Healthcare
ImmunityBio, Inc.(IBRX)
Live Price
Offline$7.36
+5.29% today
Window Change
-2.13%
Window
May 29, 2026 โ Jun 18, 2026
- Market Cap
- $7.30B
- Revenue Growth
- +668.3%
- EPS Growth
- +35.6%
- Dividend Yield
- 0.0%
Historical coverage is still filling in
This 1Y daily history view is currently sparse. Use it as directional context while we continue backfilling more history.
Coverage: 15 bars ยท May 29, 2026 โ Jun 18, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
ImmunityBio, Inc. (IBRX) is a Healthcare stock with a market cap of $7.30B and listed on NASDAQ. The stock last traded around $7.36 and down 2.1% across the available one-year price window (May 29, 2026 โ Jun 18, 2026). Baseline metrics include revenue growth of +668.3%, EPS growth of +35.6%, a dividend yield of 0.0%. What stands out right now is revenue +668.3%, EPS +35.6%, free cash flow +22.4% with operating margin -226.0% and ROIC -56.9%. Valuation already assumes a fairly strong business story at price/sales 64.4. Overall, the current profile looks closer to a higher-growth but lower-margin setup than a generic broad-market placeholder. Stock Foundry combines IBRX price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Above sector median
+668.3% vs +7.6% peer median
Operating Margin
Below sector median
-226.0% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on May 11, 2026, but the surprise data is still limited.
The operating story is still moving forward
Revenue is running at +668.3% and EPS at +35.6%, with operating margin around -226.0%.
Benchmark Edge
IBRX vs SPY, QQQ, and Sector ETFs
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
IBRX
โ
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
IBRX Max Drawdown
-10.64%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for IBRX and SPY.
Company Overview
ImmunityBio, Inc.
NASDAQ Global Select
ImmunityBio, Inc., a clinical-stage biotechnology company, develops therapies and vaccines to treat cancers and infectious diseases. It offers immunotherapy and cell therapy platforms, including antibody cytokine fusion proteins, synthetic immunomodulators, vaccine technologies, natural killer cells, and adaptive (T cell) immune systems. The company also develops therapeutic agents, which are in Phase II or III clinical trial for the treatment of liquid and solid tumors, including bladder, pancreatic, and lung cancers, as well as pathogens as SARS-CoV-2 and HIV. It has collaboration agreements with National Cancer Institute, National Institute of Deafness and Communication Disorders, and Amyris, Inc.; and license agreements with CytRx Corporation, EnGeneIC Pty Limited, GlobeImmune, Inc., and Infectious Disease Research Institute, Sanford Health, Shenzhen Beike Biotechnology Co. Ltd., Sorrento Therapeutics, Inc., and Viracta Therapeutics, Inc. The company was founded in 2014 and is based in San Diego, California.
- Leadership
- Richard Gerald Adcock
- IPO Date
- Jul 28, 2015
- Employees
- 671
- Street Address
- 3530 John Hopkins Court
- Mailing
- San Diego, CA, 92121
- Region
- San Diego, CA, US
- Reporting Currency
- USD
- Investor Line
- 858 633 0300
- Last Updated
- Apr 30, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- โ
- EV/EBITDA
- โ
- Price/Sales
- 64.4
- Price/Book
- โ
Growth
- Revenue
- +668.3%
- EPS
- +35.6%
- Free Cash Flow
- +22.4%
Profitability
- Gross Margin
- 92.4%
- Operating Margin
- -226.0%
- Net Margin
- -310.2%
- ROE
- 64.3%
- ROIC
- -56.9%
Balance Sheet
- Debt/Equity
- โ
- Current Ratio
- 5.10
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.